CYTR CytRx Corporation

0  0%
Previous Close 0.6
Open 0.59
Price To Book 0.91
Market Cap 20148863
Shares 33,637,501
Volume 51,997
Short Ratio
Av. Daily Volume 147,461

SEC filingsSee all SEC filings

  1. 8-K - Current report 19526152
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19509548
  3. 8-K - Current report 181209057
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181156205
  5. 8-K - Current report 181013472

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 poster at ASCO June 4, 2017. Abstract 11051.
Advanced sarcomas - cancer
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 completed.
Cancer - AIDS-related Kaposi’s sarcoma
Phase 2 trial completed.
Cancer - unresectable glioblastoma
Phase 2b data due 2Q 2017 according to 1Q guidance. No mention in 2Q earnings report. MIA.
Relapsed/refractory small cell lung cancer
Phase 1b dosing initiated February 2018.
Squamous Cell Carcinoma

Latest News

  1. CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
  2. CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
  3. CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
  4. CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
  5. CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
  6. CytRx Corporation to Present at the 11th Annual LD Micro Main Event
  7. Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT
  8. featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
  9. Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
  10. CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
  11. CytRx: 3Q Earnings Snapshot
  12. CytRx Corporation Reports Third Quarter 2018 Financial Results
  13. Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
  14. CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
  15. Edited Transcript of CYTR earnings conference call or presentation 6-Aug-18 3:00pm GMT
  16. CytRx Corporation to Present at the 2018 MicroCap Conference
  17. CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
  18. CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
  19. CytRx Corporation to Host Earnings Call